Long-acting injectable antipsychotics in early psychosis: A literature review

Early Intervention in Psychiatry

Volumn 7, Issue 3, 2013, Pages 247-254

  Emsley, Robin ^a   Chiliza, Bonginkosi ^a   Asmal, Laila ^a   Mashile, Mpogisheng ^a   Fusar Poli, Paolo ^b  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Depot; Early psychosis; Long acting antipsychotic; Schizophrenia

Indexed keywords

CLOZAPINE; FLUPHENAZINE; FLUPHENAZINE DECANOATE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PERPHENAZINE; PLACEBO; RISPERIDONE; ZUCLOPENTHIXOL;

AGGRESSION; AGITATION; ANXIETY; CEREBROVASCULAR ACCIDENT; DATA BASE; DEPRESSION; DRUG DOSE COMPARISON; DRUG WITHDRAWAL; GALACTORRHEA; GYNECOMASTIA; HEADACHE; HUMAN; HYPERKINESIA; HYPERPROLACTINEMIA; INFLUENZA; INJECTION SITE PAIN; INSOMNIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHOSIS; RELAPSE; REVIEW; RHINITIS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

DEPOT; EARLY PSYCHOSIS; LONG-ACTING ANTIPSYCHOTIC; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; EARLY MEDICAL INTERVENTION; HUMANS; INJECTIONS, INTRAMUSCULAR; SCHIZOPHRENIA;

EID: 84881546480     PISSN: 17517885     EISSN: 17517893     Source Type: Journal    
DOI: 10.1111/eip.12027     Document Type: Review

References (46)

1. McGorry PD, Killackey E, Yung AR. Early intervention in psychotic disorders: detection and treatment of the first episode and the critical early stages. Med J Aust 2007; 187 (7 Suppl.): S8-10.
2. Fusar-Poli P, Borgwardt S, Bechdolf A etal. The psychosis high risk state: a comprehensive state of the art review. Arch Gen Psychiatry 2012; 19: 1-14.
3. Fusar-Poli P, Bonoldi I, Yung AR etal. Predicting psychosis: a meta-analysis of transition outcomes in individuals at high clinical risk. Arch Gen Psychiatry 2012; 69: 1-10.
4. Fusar-Poli P, Bechdolf A, Taylor M etal. At risk for schizophrenic or affective psychosis? A meta-analysis of DSM/ICD diagnostic outcomes in individuals at high clinical risk. Schizophr Bull 2012 (in press).
5. Fusar-Poli P, Deste G, Smieskova R etal. Cognitive functioning in prodromal psychosis: a meta-analysis. Arch Gen Psychiatry 2012; 69: 562-571.
6. Fusar-Poli P, Radua J, McGuire P, Borgwardt S. Neuroanatomical maps of psychosis onset: voxel-wise meta-analysis of antipsychotic-naive VBM studies. Schizophr Bull 2011; 38: 1297-1307.
7. Fusar-Poli P, Borgwardt S, Crescini A etal. Neuroanatomy of vulnerability to psychosis: a voxel-based meta-analysis. Neurosci Biobehav Rev 2011; 35: 1175-1185.
8. Fusar-Poli P, Perez J, Broome M etal. Neurofunctional correlates of vulnerability to psychosis: a systematic review and meta-analysis. Neurosci Biobehav Rev 2007; 31: 465-484.
9. Fusar-Poli P, Howes OD, Allen P etal. Abnormal frontostriatal interactions in people with prodromal signs of psychosis: a multimodal imaging study. Arch Gen Psychiatry 2010; 67: 683-691.
10. Fusar-Poli P, Howes OD, Allen P etal. Abnormal prefrontal activation directly related to pre-synaptic striatal dopamine dysfunction in people at clinical high risk for psychosis. Mol Psychiatry 2011; 16: 67-75.
11. Crossley NA, Mechelli A, Fusar-Poli P etal. Superior temporal lobe dysfunction and frontotemporal dysconnectivity in subjects at risk of psychosis and in first-episode psychosis. Hum Brain Mapp 2009; 30: 4129-4137.
12. Fusar-Poli P, Meyer-Lindenberg A. Striatal presynaptic dopamine in schizophrenia, part II: meta-analysis of [18F]/[11C] DOPA PET studies. Schizophr Bull 2013; 39: 33-42.
13. Fusar-Poli P, Stone J, Broome M etal. Thalamic glutamate levels predicts cortical response during executive functioning in subjects at high risk for psychosis. Arch Gen Psychiatry 2011; 68: 881-890.
14. Howes O, Montgomery A, Asselin M etal. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch Gen Psychiatry 2009; 66: 13-20.
15. Kane JM, Garcia-Ribera C. Clinical guideline recommendations for antipsychotic long-acting injections. Br J Psychiatry Suppl 2009; 52: S63-67.
16. Ascher-Svanum H, Zhu BJ, Faries DE etal. The cost of relapse and the predictors of relapse in the treatment of schizo-phrenia. BMC Psychiatry 2010; 10: 2 doi: 10.1186/1471-244X-10-2.
17. Lieberman JA, Stroup TS. The NIMH-CATIE Schizophrenia Study: what did we learn? Am J Psychiatry 2011; 168: 770-775.
18. Robinson D, Woerner MG, Alvir JM etal. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999; 56: 241-247.
19. Coldham EL, Addington J, Addington D. Medication adherence of individuals with a first episode of psychosis. Acta Psychiatr Scand 2002; 106: 286-290.
20. Emsley R, Chiliza B, Asmal L, de Fleuriot M. Long acting injectable antipsychotics in early psychosis. In: Haddad P, Lambert T, Lauriello J, eds. Antipsychotic Long Acting Injections. Oxford: Oxford University Press, 2010; 145-162.
21. Jaeger M, Rossler W. Attitudes towards long-acting depot antipsychotics: a survey of patients, relatives and psychiatrists. Psychiatry Res 2010; 175: 58-62.
22. Kane JM, Rifkin A, Quitkin F, Nayak D, Ramos-Lorenzi J. Fluphenazine vs placebo in patients with remitted, acute first-episode schizophrenia. Arch Gen Psychiatry 1982; 39: 70-73.
23. Tiihonen J, Wahlbeck K, Lonnqvist J etal. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ 2006; 333: 224.
24. Verma S, Subramaniam M, Abdin E etal. Safety and efficacy of long-acting injectable risperidone in patients with schizophrenia spectrum disorders: a 6-month open-label trial in Asian patients. Hum Psychopharmacol 2010; 25: 230-235.
25. Napryeyenko O, Burba B, Martinez G etal. Risperidone long-acting injectable in recent-onset schizophrenia examined with clinician and patient self-report measures. J Clin Psychopharmacol 2010; 30: 200-202.
26. Rabinowitz J, Napryeyenko O, Burba B etal. Premorbid functioning and treatment response in recent-onset schizophrenia: prospective study with risperidone long-acting injectable. J Clin Psychopharmacol 2011; 31: 75-81.
27. Schooler N, Rabinowitz J, Davidson M etal. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry 2005; 162: 947-953.
28. Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies. Clin Ther 2008; 30: 2378-2386.
29. Bossie CA, Fu DJ, Sliwa JK, Ma YW, Alphs L. Tolerability of initiation doses of once-monthly paliperidone palmitate in patients with recently diagnosed schizophrenia in anacute treatment trial. Ther Adv Psychopharmacol 2011; 1: 111-124.
30. Hough D, Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res 2010; 116: 107-117.
31. Tiihonen J, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry 2011; 168: 603-609.
32. Nuechterlein KH, Dawson ME, Gitlin M etal. Developmental Processes in Schizophrenic Disorders: longitudinal studies of vulnerability and stress. Schizophr Bull 1992; 18: 387-425.
33. Ventura J, Subotnik KL, Guzik LH etal. Remission and recovery during the first outpatient year of the early course of schizophrenia. Schizophr Res 2011; 132: 18-23.
34. Moller HJ, Llorca PM, Sacchetti E, Martin SD, Medori R, Parellada E. Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. Int Clin Psychopharmacol 2005; 20: 121-130.
35. Parellada E, Andrezina R, Milanova V etal. Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable. J Psychopharmacol 2005; 19 (5 Suppl.): 5-14.
36. Fleischhacker WW, Eerdekens M, Karcher K etal. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry 2003; 64: 1250-1257.
37. Lasser RA, Bossie CA, Zhu Y, Locklear JC, Kane JM. Long-acting risperidone in young adults with early schizophrenia or schizoaffective illness. Ann Clin Psychiatry 2007; 19: 65-71.
38. Weiden PJ, Schooler NR, Weedon JC, Elmouchtari A, Sunakawa A, Goldfinger SM. A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome. J Clin Psychiatry 2009; 70: 1397-1406.
39. Kim B, Lee SH, Choi TK etal. Effectiveness of risperidone long-acting injection in first-episode schizophrenia: in naturalistic setting. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 1231-1235.
40. Macfadden W, Bossie CA, Turkoz I, Haskins JT. Risperidone long-acting therapy in stable patients with recently diagnosed schizophrenia. Int Clin Psychopharmacol 2010; 25: 75-82.
41. Bartzokis G, Lu PH, Amar CP etal. Long acting injection versus oral risperidone in first-episode schizophrenia: differential impact on white matter myelination trajectory. Schizophr Res 2011; 132: 35-41.
42. Emsley R, Medori R, Koen L, Oosthuizen PP, Niehaus DJ, Rabinowitz J. Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: a preliminary study. J Clin Psychopharmacol 2008; 28: 210-213.
43. Andreasen NC, Carpenter WT Jr, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 2005; 162: 441-449.
44. Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J. Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: a study with risperidone long-acting injection. Int Clin Psychopharmacol 2008; 23: 325-331.
45. Detke HC, Correll CU, Liu C, Landry J, Feldman PD, McDonnell DP. Comparison of outcome in patients with early phase versus later phase schizophrenia. 3rd Schizophrenia International Research Society (SIRS) Conference; Florence, Italy; April 2012.
46. Alphs L, Bossie CA, Kern-Sliwa J, Ma YW, Haskins JT. Paliperidone palmitate: Clinical response in subjects with schizophrenia with recent v. longer-term duration of illness. 162nd Annual Meeting of the American Psychiatric Association (APA), San Francisco, 2009. New Research Abstracts. NR6-027 p. 235.